GlassScriptPhysician profile
Deepshikha Sharda
NPI 1427006857
$2,403.15
in general payments reported to CMS, 2019-2025
16 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $490 · 2023: $887 · 2024: $715 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,768.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,074.60 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $640.40 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $231.81 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $89.22 | 2022-2024 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Exact Sciences Corporation | $83.22 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $62.42 | 2022 | |
| Sanofi Pasteur INC. | $33.27 | 2023 | |
| Merck Sharp & Dohme LLC | $31.41 | 2022-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Dynavax Technologies Corporation | $31.01 | 2023 | Heplisav-B |
| Eisai INC. | $23.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.05 | 2022 | |
| Abbvie INC. | $18.79 | 2022 | |
| Ibsa Pharma INC. | $18.77 | 2025 | Flector, Licart, Tirosint |
| Phadia US INC. | $17.16 | 2023 | Immunocap |
| Idorsia Pharmaceuticals US INC | $14.84 | 2024 | Quviviq |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $13.45 | 2023 | Grastek, Ragwitek, Odactra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepshikha Sharda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.